In a laboratory at the Australian National University, a device small enough to fit in a pocket may be rewriting the timeline of one of humanity's most feared diseases. Dr Shankar Dutt and his team have developed nanopore sensors capable of identifying individual protein molecules in blood, offering the possibility of detecting Alzheimer's disease up to 15 years before a single symptom appears. At a moment when dementia claims more than 17,500 Australian lives each year — a toll that has risen nearly 40 percent in a decade — this technology arrives as a rare convergence of precision science an
ANU nanopore sensors could detect Alzheimer's 15 years early
Dementia accounts for 17,500+ Australian deaths annually with a 39% increase over the past decade, making early detection critical for patient outcomes.
You are essentially looking for a drop of blood in an ocean.
Mark
Why does detecting a single molecule matter so much more than detecting many at once?
Mimi
Because the proteins that signal Alzheimer's are present in blood at vanishingly low concentrations. Conventional methods need enough molecules to create a measurable signal. Nanopores detect one molecule at a time, so even a single protein can be found and identified.
Mark
And the 15-year window—how confident are you in that timeline?
Mimi
Those are preliminary results. We're still validating them. But the principle is sound: the proteins start accumulating in the brain long before symptoms appear, and they leak into the blood. If we can reliably measure them, we can catch the disease when intervention still works.
Mark
What's the hardest part of turning this into something a doctor can actually use?
Mimi
Making sure it works reliably on real blood from real people. Blood is messy—different viscosity, different cell counts, different protein backgrounds depending on who you are. The silicon chip works beautifully in controlled conditions. The challenge is making it work when conditions aren't controlled.
Mark
You mentioned spinal taps are unpleasant. Is that why early detection hasn't happened before?
Mimi
Partly. A spinal tap is invasive enough that you can't do it routinely to screen healthy people. But also, the technology didn't exist. You need something sensitive enough to find those rare proteins, and portable enough that it's practical. That's what nanopores give us.
Mark
What happens if someone tests positive 15 years before symptoms?
Mimi
That's the whole point. Current Alzheimer's drugs work best early, before irreversible damage occurs. And lifestyle changes—diet, exercise, cognitive engagement—can slow progression. Right now we can't intervene because we don't know who needs it. Early detection changes that.
Mark
How long until this is actually available?
Mimi
Realistically, five to seven years before the public can access it. We need to finish the development work, run clinical trials, get regulatory approval. It's not quick, but it's faster than waiting for symptoms to appear.
The Pulse
- Dementia is now Australia's leading cause of death, yet it remains almost invisible until the brain damage it causes has already passed the point of reversal — a diagnostic gap that costs lives every year.
- Conventional blood tests cannot detect the vanishingly rare proteins that signal early Alzheimer's, leaving clinicians without a practical tool for the window when intervention would matter most.
- Dutt's nanopore chips — each just five millimetres across and riddled with holes a fraction of a hair's width — read the electrical signature of individual molecules passing through, achieving a sensitivity that standard pathology cannot approach.
- The device connects to a laptop by USB and returns results in 10 to 15 minutes, transforming what currently requires an invasive spinal tap into something closer to a routine blood screen.
- Clinical trials are still five to seven years away, and the team must first prove the technology holds up across variations in blood type and composition before laboratory promise becomes hospital reality.
- The same platform is already being aimed at pancreatic cancer and environmental heavy-metal contamination in water, suggesting a single scientific breakthrough with consequences well beyond Alzheimer's.
In a laboratory at the Australian National University, a device small enough to fit in a pocket may be rewriting the timeline of one of humanity's most feared diseases. Dr Shankar Dutt and his team have developed nanopore sensors capable of identifying individual protein molecules in blood, offering the possibility of detecting Alzheimer's disease up to 15 years before a single symptom appears. At a moment when dementia claims more than 17,500 Australian lives each year — a toll that has risen nearly 40 percent in a decade — this technology arrives as a rare convergence of precision science and human urgency. The question it poses is ancient even if the method is new: how early can we see what is coming, and what might we do differently if we could?
Dr Shankar Dutt works with a device no larger than a smartphone, built around a silicon chip five millimetres across and perforated with holes so small that ten thousand of them would span a single human hair. Inside those nanoscale pores, individual protein molecules leave electrical fingerprints — and it is in those fingerprints that Dutt believes Alzheimer's disease can be caught up to 15 years before a person notices anything is wrong.
The stakes are considerable. Dementia kills more than 17,500 Australians each year, a figure that has climbed 39 percent over the past decade. By the time memory loss becomes apparent, the underlying brain damage has already progressed beyond what current treatments can reverse. Those treatments work best early — but conventional medicine has no reliable way to find the disease in that early window. Standard blood tests can identify proteins at reasonable concentrations, but the markers for early Alzheimer's exist in quantities Dutt describes as a drop of blood in an ocean. Nanopore sensing sidesteps this by measuring one molecule at a time.
The nanopores themselves are made using the ANU's Heavy Ion Accelerator Facility, where gold ions travelling at 20,000 kilometres per second are fired through ultra-thin silicon — a process Dutt likens to shooting a bullet through paper. The resulting pores sit between two salt solutions. A voltage drives ions through, creating a steady electrical current; when a protein enters the pore, it disrupts that current in a way that is both measurable and unique. Machine-learning software then reads those disruptions to identify what has passed through.
For patients, the practical shift is significant. Detecting these proteins today requires a spinal tap — invasive and infrequent. A portable device producing results in 10 to 15 minutes via USB connection makes regular screening conceivable, and with it, the possibility of lifestyle changes or drug interventions before irreversible damage sets in.
The team is extending the same platform toward pancreatic cancer detection and environmental monitoring — identifying heavy metals in waterways at concentrations too low for current portable methods, a gap that matters wherever bushfires or mining activity threaten drinking water. Dutt estimates five to seven years before nanopore blood analysis reaches the public, with two to three years needed to build a device pathology staff can routinely operate, followed by up to four years of clinical trials. The work of ensuring the technology handles real-world variation in blood type and composition remains ongoing. "If we can take it to clinical stage," Dutt said, "that will be really, really helpful for not just Australians but all over the world."
Dr Shankar Dutt stood in a laboratory at the Australian National University's Research School of Physics, holding a device no larger than a smartphone. Inside it sat a silicon chip five millimetres across, studded with holes so impossibly small that ten thousand of them could fit across the width of a human hair. This is where the future of Alzheimer's detection lives—in spaces invisible to the naked eye, where individual protein molecules leave electrical fingerprints as they pass through nanoscale pores.
Dutt's work has earned him the Symal Innovation Award at the 2026 7NEWS Young Achiever Awards NSW/ACT, recognition for research that could reshape how we catch one of Australia's most relentless killers. Dementia now accounts for more than 17,500 deaths annually in the country, a figure that has climbed 39 percent over the past decade as the population ages. Yet the disease remains stubbornly difficult to diagnose until it is already too late. By the time memory loss becomes noticeable, the underlying damage in the brain has progressed beyond reversal. Current treatments work best in early stages, but conventional medicine has no reliable way to find those early stages before symptoms announce themselves.
Dutt's nanopore sensors offer a different path. The technology works by detecting individual molecules—a capability that conventional pathology methods cannot match. Standard tests can identify proteins when they exist in reasonable concentrations, but they falter when searching for rare targets. "There are around 10,000 proteins in blood," Dutt explained. "It's like finding a needle in a haystack, but even harder than that. You are essentially looking for a drop of blood in an ocean." Nanopore sensing bypasses this limitation entirely by measuring one molecule at a time, capturing what Dutt calls an "electrical fingerprint" as each protein passes through the pore.
The creation of these nanopores is itself a feat of precision. Researchers use the ANU's Heavy Ion Accelerator Facility to fire gold ions traveling at 20,000 kilometres per second through extremely thin silicon—a process Dutt compares to firing a bullet through paper. The resulting holes sit between two salt solutions. When voltage drives ions through the pore, it creates a measurable electrical current. When a protein, DNA, or RNA molecule enters the pore, it disrupts that flow, producing a detectable change in current. Artificial intelligence and machine-learning software then analyze these electrical signatures to identify which protein has passed through.
Preliminary results suggest the technology can detect proteins associated with Alzheimer's disease up to 15 years before symptoms appear. This window matters enormously. Nerve cells breaking down in the brain release proteins, but the blood-brain barrier allows only tiny concentrations to reach the bloodstream. Currently, detecting these proteins requires a spinal tap—invasive, uncomfortable, and not something patients can undergo regularly. A portable device that produces results in 10 to 15 minutes, connected to a laptop by USB, changes the equation entirely. It makes screening feasible, regular monitoring possible, and early intervention realistic.
The team is also exploring whether the same platform could catch pancreatic cancer in its early stages, a disease that typically remains hidden until it has advanced beyond treatment. One PhD researcher is investigating the technology's potential for environmental monitoring—detecting heavy metals in water at concentrations too low for current portable methods to catch. Bushfires can drive heavy metals accumulated in trees into waterways; mines release metal ions that sicken people if they reach drinking water supplies. Organizations like Icon Water test regularly, but Dutt sees a gap in sensitivity that his technology could fill.
The path to widespread use remains measured. Dutt estimates five to seven years before the public can give blood and receive results from nanopore analysis. A device that pathology staff can routinely operate might take two to three years to develop, followed by up to four years of clinical trials. The team is currently working to ensure the technology handles variations in blood type, blood thickness, and other blood-related conditions—practical challenges that separate laboratory success from clinical reality. "If we can take it to clinical stage, that will be really, really helpful for not just Australians but all over the world," Dutt said. The needle in the haystack, it seems, is finally within reach.
Notable Quotes
By the time we are there, the disease has already progressed; there is no coming back. There is a big need to detect Alzheimer's in the early stage, so that we can take these drugs or even change our lifestyle to slow down the progression of disease.— Dr Shankar Dutt
If we can take it to clinical stage, that will be really, really helpful for not just Australians but all over the world.— Dr Shankar Dutt
Want the full story?
Read the original at Canberra Daily ↗
Health & Medicine